Observational study finds sildenafil use linked to improved survival rates in cancer patients — Evidence Review

A large observational study suggests that sildenafil (Viagra) may limit cancer metastasis by disrupting cholesterol transport within cancer cells, and survival rates appear higher among cancer patients using sildenafil—especially in combination with statins. Most related studies support beneficial or neutral effects of sildenafil on cancer progression, though some research highlights potential risks in specific cancers.

• Multiple preclinical and clinical studies report that phosphodiesterase-5 inhibitors (like sildenafil) can suppress tumor growth, enhance immune responses, and improve the effects of chemotherapy, but results vary by cancer type and context 1 3 5 7 9 11.
• Some studies indicate no increase in tumor recurrence or metastasis with sildenafil use in prostate cancer, while others note a potential increase in melanoma risk, suggesting effects may depend on tumor biology and patient characteristics 2 4 6 10.
• The newly identified mechanism—interfering with cancer cell cholesterol trafficking—adds a distinct mode of action to previously reported immunological and vascular effects, and the potential synergy with statins is a novel aspect not widely explored in earlier research 1 5 11.

Study Overview and Key Findings

Understanding how commonly used drugs like sildenafil might affect cancer progression is of significant interest, given their widespread use and potential off-target effects. This study, led by researchers at the Weizmann Institute of Science and collaborators, is notable for uncovering a previously unrecognized biological pathway linking cGMP signaling (the pathway affected by sildenafil) to cholesterol transport inside cancer cells—a process critical for metastasis. The large population-based analysis, together with experimental data, provides a broad foundation for the findings.

Property	Value
Study Year	2026
Organization	Weizmann Institute of Science, U.S. National Cancer Institute, Clalit Health Services, Rabin Medical Center
Journal Name	Cancer Research
Authors	Yarden Ariav, Samah Hayek, Thomas Cantore, Neel Sanghvi, Lital N. Adler, Naama Darzi, Lipika R. Pal, David Robert Crawford, Tomer Malleron, Josh Silverbeck, Eliane Yardeni, Emma Hajaj, Efrat Ben-Zeev, Sanju Sinha, Shahar Ziman, Amir Shlomai, Sergey Malitsky, Maxim Itkin, Smadar Levin-Zaidman, Inna Goliand, Omer Goldman, Hila Tishler, Alexander Brandis, Tevie Mehlman, Yuri Kuznetsov, Noga Kozer, Karen Shamash, Ella Itzhaki, Neta Ben-Chaim Moskovits, Dean Ranmar, Salomon M. Stemmer, Shay Ben-Shachar, Eytan Ruppin, Ayelet Erez
Population	Cancer patients, including those using sildenafil and statins
Sample Size	about 5 million Clalit members
Methods	Observational Study
Outcome	Survival rates among cancer patients using sildenafil and statins
Results	Sildenafil use associated with significantly better survival in cancer patients.

Literature Review: Related Studies

To place these findings in context, we searched the Consensus scientific paper database (over 200 million papers) using the following queries:

1. sildenafil cancer cell metastasis
2. viagra survival rates cancer patients
3. mechanisms sildenafil tumor growth inhibition

Topic	Key Findings
Does sildenafil or PDE5 inhibition affect cancer metastasis and recurrence?	- PDE5 inhibitors reduce postoperative metastasis and restore immune function in cancer surgery models, supporting antimetastatic potential 1 7. - Randomized and cohort studies find no evidence that sildenafil promotes prostate cancer growth or recurrence 2 6.
What mechanisms underlie sildenafil’s effects on tumor biology?	- Sildenafil disrupts tumor-promoting immune suppression and may inhibit cell proliferation, induce apoptosis, and impair angiogenesis in several cancer models 1 5 7 9 11. - The drug may also affect cholesterol transport and cGMP pathways, impacting tumor cell survival 8 9.
Are there cancer types where sildenafil use may increase risk?	- Some evidence links sildenafil use to increased melanoma risk, possibly via cGMP-dependent pathways that promote melanoma cell growth 4 10.
Can sildenafil enhance the efficacy of other cancer therapies?	- Sildenafil potentiates the antitumor activity of chemotherapies like cisplatin and doxorubicin, and may act synergistically with other drugs such as statins or kinase inhibitors 3 5 11.

Does sildenafil or PDE5 inhibition affect cancer metastasis and recurrence?

Several studies indicate that PDE5 inhibitors may reduce metastasis and do not promote tumor recurrence in most cancer models. Experimental models show that sildenafil can reverse immune suppression after cancer surgery and reduce metastatic spread, especially by targeting myeloid-derived suppressor cells (MDSCs) 1 7. Randomized and cohort studies in prostate cancer patients found no increased risk of tumor recurrence or metastasis associated with sildenafil use 2 6.

• PDE5 inhibition reverses surgery-induced immunosuppression and reduces postoperative metastasis in preclinical models 1.
• Animal and patient studies show no promotion of tumor growth or biochemical recurrence with sildenafil in prostate cancer 2 6.
• The new study's finding that sildenafil disrupts metastasis aligns with evidence from immune and tumor models 1 7.
• While evidence supports safety in certain cancers, risk profiles may vary by cancer type and patient context 2 6.

What mechanisms underlie sildenafil’s effects on tumor biology?

A range of mechanisms have been proposed for sildenafil’s antitumor effects, including modulation of immune suppression, induction of apoptosis, inhibition of proliferation, anti-angiogenic effects, and interference with cholesterol trafficking. Several studies show that sildenafil and other PDE5 inhibitors reduce MDSC activity, restore T-cell function, and impair tumor growth through both immune and metabolic pathways 1 5 7 9 11. The new study extends these findings by describing how sildenafil disrupts intracellular cholesterol transport, a key factor in cancer cell survival and metastasis.

• Sildenafil impairs tumor immune evasion by reducing MDSC function and enhancing T-cell responses 1 7.
• The drug induces apoptosis and inhibits proliferation in multiple cancer cell types, including colorectal and breast cancers 5 9 11.
• Interference with cholesterol trafficking provides a new metabolic mechanism, which may combine with previously known immunological and vascular effects 8 9.
• The combination with statins or other agents may further restrict tumor growth by targeting multiple pathways 5 11.

Are there cancer types where sildenafil use may increase risk?

While most studies report neutral or beneficial effects on tumor growth, some research suggests that sildenafil may increase the risk of melanoma. Prospective cohort and experimental studies link sildenafil use to elevated melanoma risk, potentially through enhancement of cGMP-dependent growth pathways in melanoma cells 4 10. These findings highlight the importance of cancer-specific effects and the need for further stratification in future research.

• Epidemiological data show an association between sildenafil use and increased incidence of melanoma in men 4.
• Laboratory studies demonstrate that sildenafil can potentiate growth-promoting cGMP pathways in melanoma cells 10.
• No such risk was observed in prostate cancer cohorts, indicating possible tumor-type specificity 2 6.
• The new study did not address melanoma specifically, so caution may be warranted in interpreting its findings for all cancers 4 10.

Can sildenafil enhance the efficacy of other cancer therapies?

Multiple studies have examined combinations of sildenafil with standard cancer therapies. Preclinical models find that sildenafil enhances the delivery and efficacy of chemotherapeutic agents like doxorubicin and cisplatin, sometimes leading to significantly reduced tumor volumes compared to chemotherapy alone 3 5 11. The new study's observation that statins may increase the antimetastatic effect of sildenafil is supported by similar reports of synergistic effects with other agents.

• Sildenafil increases tumor drug uptake and boosts cytotoxic effects of doxorubicin in breast cancer models 3.
• The drug potentiates cisplatin's antitumor activity by promoting apoptosis and inhibiting angiogenesis 5.
• Combining sildenafil with kinase inhibitors (e.g., sorafenib) has been shown to enhance tumor cell death in vitro and in vivo 11.
• The potential for combination with statins as explored in the new study is a logical extension of these findings 5 11.

Future Research Questions

While current evidence suggests that sildenafil may have antimetastatic and survival benefits in certain cancers, additional research is necessary to clarify its effects across different cancer types, mechanisms, and patient populations. Key questions remain regarding long-term safety, optimal combinations, and potential risks in vulnerable subgroups.

Research Question	Relevance
Does long-term sildenafil use affect cancer recurrence and metastasis risk across different cancer types?	Important for understanding generalizability and safety, as some studies suggest neutral or beneficial effects in certain cancers, but possible increased risk in melanoma 2 4 6 10.
What are the molecular mechanisms by which sildenafil modulates cholesterol trafficking and tumor cell survival?	Further mechanistic studies could clarify how cholesterol transport disruption interacts with immune and metabolic pathways, building on both the new and existing findings 1 5 7 8 9 11.
Does combining sildenafil with statins or other metabolic therapies improve cancer outcomes in clinical trials?	The new study suggests synergy with statins, but prospective randomized trials are needed to confirm improved outcomes and safety 5 11.
What is the impact of sildenafil on tumor immune microenvironment in humans?	Preclinical studies show immune modulation, but human data are limited; understanding this could inform combination immunotherapies 1 7.
Are there specific patient populations or genetic backgrounds that modify the effects of sildenafil on cancer progression?	Some evidence points to tumor-type and genetic context specificity, such as increased melanoma risk in certain groups 4 10; identifying modifiers is key for personalized medicine.